Showing 2851-2860 of 4166 results for "".
- Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of Eyetelligence Clinical Decision Support Softwarehttps://modernod.com/news/bausch-lomb-and-lochan-enter-into-agreement-to-develop-the-next-generation-of-eyetelligence-clinical-decision-support-software/2479271/Bausch + Lomb announced that its affiliate has entered into an agreement with Lochan LLC to develop the next-generation of Bausch + Lomb’s eyeTELLIGENCE clinical decision support software. Using the existing cloud-based infrastructure of eyeTELLIGENCE, this analytical software is being designed t
- Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302 Anti-VEGF for Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-the-phase-2-clinical-trial-of-ibi302-anti-vegf-for-wet-amd/2479137/Innovent Biologics announces that the first patient has been successfully dosed in a phase 2 clinical trial for IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein. This study is a randomized, double-blind, multicenter, active-cont
- Accure Therapeutics Enrolls First Patient in Phase 2 Clinical Trial on Acute Optic Neuritishttps://modernod.com/news/accure-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-on-acute-optic-neuritis/2478923/Accure Therapeutics announced it has enrolled the first patient in its ACUITY phase 2 clinical trial in patients with acute optic neuritis (AON). A total of 36 patients will be enrolled in two randomized parallel groups. They will be followed for 6 months to measure and assess safety and prelimin
- LumiThera Completes Patient Enrollment in LIGHTSITE III Clinical Study to Treat Dry AMDhttps://modernod.com/news/lumithera-completes-patient-enrollment-in-the-lightsite-iii-clinical-study-to-treat-dry-amd/2478882/LumiThera announced it has completed enrollment in its multicenter US clinical study in non-neovascular (dry) age-related macular degeneration (AMD) patients. The randomized, multicenter study, LIGHTSITE III, enrolled the last patient at the Byers Eye Insti
- LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-positive-interim-data-in-visual-and-erg-clinical-outcomes-in-the-electrolight-pilot-study-in-dry-amd-patients/2478872/LumiThera announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. A total of 23 eyes from 15 subjects with intermediate dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda Light Delivery System (3 times per week for 3 we
- GenSight Biologics Announces Publication of Results from Lumevoq Phase 1/2a Clinical Trial REVEAL in BioDrugshttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-phase-1-2a-clinical-trial-reveal-in-biodrugs/2478868/GenSight Biologics announced that the journal BioDrugs has published results from REVEAL, the phase 1/2a clinical trial that evaluated the safety of Lumevoq gene therapy in subjects with ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the ph
- JCRS Publishes Phase 2 Nepafenac Clinical Trial With Evolute Sustained Drug Delivery Systemhttps://modernod.com/news/jcrs-publishes-phase-2-nepafenac-clinical-trial-with-evolute-sustained-drug-delivery-system/2478843/Mati Therapeutics announced that a peer reviewed manuscript of a phase 2 clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refractive Surgery
- Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401 for Thyroid Eye Diseasehttps://modernod.com/news/immunovant-announces-voluntary-pause-in-clinical-dosing-of-imvt-1401-for-thyroid-eye-disease/2478829/Immunovant announced a voluntary pause of dosing in its ongoing clinical trials of its investigational drug IMVT-1401 for the treatment of Thyroid Eye Disease (TED). The company has become aware of a physiological signal consisting of elevated total cholesterol and LDL levels
- Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-enrollment-in-mira-2-phase-3-clinical-trial-investigating-nyxol-for-reversal-of-mydriasis/2478719/Ocuphire Pharma announced that it has completed enrollment earlier than expected in its MIRA-2 phase 3 registration clinical trial evaluating the safety and efficacy of Nyxol to reverse pharmacologically-induced mydriasis. “We are pleased to exceed our enrollment target and reach this impo
- CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidatehttps://modernod.com/news/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/2478683/CureVac NV announced that the first participant in a clinical phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a